Perna, John
Bellato, Alessio
Ganapathy, Preethi S. http://orcid.org/0000-0001-5736-7485
Solmi, Marco http://orcid.org/0000-0003-4877-7233
Zampieri, Andrea
Faraone, Stephen V. http://orcid.org/0000-0002-9217-3982
Cortese, Samuele
Article History
Received: 3 February 2023
Revised: 15 May 2023
Accepted: 16 June 2023
First Online: 26 July 2023
Change Date: 9 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41380-023-02212-x
Competing interests
: In the past year, SVF received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Aardwolf, Akili, Atentiv, Corium, Genomind, Ironshore, Medice, Noven, Otsuka, Sandoz, Sky Therapeutics, Supernus, Tris, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Alcobra, Arbor, Aveksham, Axsome, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, KemPharm, Lundbeck/Takeda, Shire/Takeda, McNeil, NeuroLifeSciences, Neurovance, Novartis, Pfizer, Rhodes, Shire, and Sunovion. He also receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i>; Oxford University Press: <i>Schizophrenia: The Facts;</i> and Elsevier: <i>ADHD: Non-Pharmacologic Interventions</i>. In addition, he is the program director of . SVF is supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381; NIMH grants U01AR076092-01A1, 1R21MH1264940, R01MH116037; 1R01NS128535 – 01; Oregon Health and Science University, Otsuka Pharmaceuticals, Noven Pharmaceuticals Incorporated, and Supernus Pharmaceutical Company. SC declares honoraria and reimbursement for travel and accommodation expenses for lectures from the following non-profit associations: Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD Alliance Resource (CADDRA), and British Association of Pharmacology (BAP), for educational activity on ADHD. All other authors declare no competing interests.